Decision 2001/75 - 2001/75/EC: Commission Decision of 18 January 2001 for safety and potency testing of foot-and-mouth disease vaccines and bluetongue vaccines (notified under document number C(2001) 118)

Please note

This page contains a limited version of this dossier in the EU Monitor.

1.

Current status

This decision has been published on January 27, 2001 and should have been implemented in national regulation on the same day at the latest.

2.

Key information

official title

2001/75/EC: Commission Decision of 18 January 2001 for safety and potency testing of foot-and-mouth disease vaccines and bluetongue vaccines (notified under document number C(2001) 118)
 
Legal instrument Decision
Number legal act Decision 2001/75
CELEX number i 32001D0075

3.

Key dates

Document 18-01-2001
Publication in Official Journal 27-01-2001; Special edition in Estonian: Chapter 03 Volume 031,Special edition in Croatian: Chapter 03 Volume 042,Special edition in Bulgarian: Chapter 03 Volume 036,Special edition in Lithuanian: Chapter 03 Volume 031,Special edition in Romanian: Chapter 03 Volume 036,Special edition in Latvian: Chapter 03 Volume 031,Special edition in Hungarian: Chapter 03 Volume 031,OJ L 26, 27.1.2001,Special edition in Polish: Chapter 03 Volume 031,Special edition in Czech: Chapter 03 Volume 031,Special edition in Maltese: Chapter 03 Volume 031,Special edition in Slovak: Chapter 03 Volume 031,Special edition in Slovenian: Chapter 03 Volume 031
Effect 27-01-2001; Takes effect Date notif.
End of validity 31-12-9999
Notification 27-01-2001; {titleAndReference.draft.disclaimer.new|http://publications.europa.eu/resource/authority/fd_365/titleAndReference.draft.disclaimer.new}

4.

Legislative text

Avis juridique important

|

5.

32001D0075

2001/75/EC: Commission Decision of 18 January 2001 for safety and potency testing of foot-and-mouth disease vaccines and bluetongue vaccines (notified under document number C(2001) 118)

Official Journal L 026 , 27/01/2001 P. 0038 - 0039

Commission Decision

of 18 January 2001

for safety and potency testing of foot-and-mouth disease vaccines and bluetongue vaccines

(notified under document number C(2001) 118)

(2001/75/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Council Decision 90/424/EEC of 26 June 1990 on expenditure in the veterinary field(1), as last amended by Regulation (EC) No 1258/1999(2), and in particular Articles 6 and 14 thereof,

Having regard to Council Decision 91/666/EEC of 11 December 1991 establishing Community reserves of foot-and-mouth disease vaccines(3), as last amended by Decision 1999/762/EC(4), and in particular Article 5 thereof,

Whereas:

  • (1) 
    In conformity with Decision 91/666/EEC, the purchase of antigens is a part of the Community action to establish Community reserves of foot-and-mouth disease vaccines.
  • (2) 
    By Commission Decision 93/590/EC of 5 November 1993 for the purchase by the Community of foot-and-mouth disease antigens within the framework of the Community action concerning reserves of foot-and-mouth disease vaccines(5), as last amended by Decision 95/471/EC(6), arrangements were made for purchase of A5, A22 and O1 foot-and-mouth disease antigen.
  • (3) 
    Foot-and-mouth disease virus antigens kept in the emergency stock since 1993 must be tested with regard to safety and potency to ensure that the antigen reserves kept for emergency use are of high quality.
  • (4) 
    By Commission Decision 98/64/EC of 9 December 1997 on a Community financial contribution for improving the foot-and-mouth disease control programme in Turkey(7), it was agreed as a part of a work plan that the European Commission would make arrangements for testing of foot-and-mouth disease vaccine produced in Turkey.
  • (5) 
    By Commission Decision 2000/292/EC of 6 April 2000 for purchase by the Community of bluetongue vaccine for emergency stock(8), arrangements were made for purchase of bluetongue vaccine for emergency.
  • (6) 
    No bluetongue vaccine is produced by the pharmaceutical industry based in the Member States of the European Union (EU).
  • (7) 
    Bluetongue vaccine purchased abroad for emergency use should be tested with the objective of obtaining information of importance for the use of the vaccine under different epidemiological conditions.
  • (8) 
    Safety and potency testing of foot-and-mouth disease vaccine and bluetongue vaccine can only be carried out at laboratories being operated under approved biosecurity levels.
  • (9) 
    The measures provided for in this Decision are in accordance with the opinion of the Standing Veterinary Committee,

HAS ADOPTED THIS DECISION:

Article 1

  • 1. 
    The Community shall make arrangements for appropriate safety and potency testing of:
  • foot-and-mouth disease virus antigens purchased in 1993 and since then kept as a part of the EU emergency stock,
  • foot-and-mouth disease vaccine produced in Turkey and used in a prophylactic vaccination programme which includes vaccination of susceptible animals kept in the area of Turkish Thrace,
  • bluetongue vaccines produced outside the European Community and purchased for an emergency stock.
  • 2. 
    The maximum cost of the measures referred to in paragraph 1 shall be up to EUR 430000.

Article 2

The measures mentioned in Article 1 shall be carried out by the Commission in cooperation with the supplier designated by call for tender.

Article 3

  • 1. 
    To meet the objectives of Articles 1 and 2 the Commission shall conclude...

More

This text has been adopted from EUR-Lex.

 

6.

Sources and disclaimer

For further information you may want to consult the following sources that have been used to compile this dossier:

This dossier is compiled each night drawing from aforementioned sources through automated processes. We have invested a great deal in optimising the programming underlying these processes. However, we cannot guarantee the sources we draw our information from nor the resulting dossier are without fault.

 

7.

Full version

This page is also available in a full version containing the legal context, de Europese rechtsgrond, other dossiers related to the dossier at hand and the related cases of the European Court of Justice.

The full version is available for registered users of the EU Monitor by ANP and PDC Informatie Architectuur.

8.

EU Monitor

The EU Monitor enables its users to keep track of the European process of lawmaking, focusing on the relevant dossiers. It automatically signals developments in your chosen topics of interest. Apologies to unregistered users, we can no longer add new users.This service will discontinue in the near future.